Previous 10 |
Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions, and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday, look f...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. The market is moving in the right direction after some cooling off of Washington-Be...
OptiNose, Inc. (OPTN) Q2 2018 Earnings Conference Call August 14, 2018 8:00 AM ET Executives Peter Miller - Chief Executive Officer, Board of Directors Keith Goldan - Chief Financial Officer Tom Gibbs - Chief Commercial Officer Jonathan Neely - VP, IR Analysts David Amsel...
Gainers: THST +50% . LEVB +21% . HYRE +21% . LAC +19% . XERS +15% . TAOP +15% . TPR +14% . SVT +14% . XOMA +13% . IDRA +13% . More news on: Truett-Hurst, Inc., Level Brands, Inc., HyreCar, Stocks on the move, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
YARDLEY, Pa., June 27, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that XHANCE ® (fluticasone propionate) has been added to Express Scripts’ nationa...
YARDLEY, Pa., May 17, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that members of its management team will present a company overview and business update at the H.C...
2024-05-15 10:30:03 ET Lake Street analyst issues BUY recommendation for OPTN on May 15, 2024 08:43AM ET. The previous analyst recommendation was Buy. OPTN was trading at $1.13 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analy...